U.S. flag

An official website of the United States government

NM_003954.5(MAP3K14):c.2437C>A (p.Pro813Thr) AND NIK deficiency

Germline classification:
Uncertain significance (1 submission)
Last evaluated:
Dec 13, 2021
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV003088901.1

Allele description [Variation Report for NM_003954.5(MAP3K14):c.2437C>A (p.Pro813Thr)]

NM_003954.5(MAP3K14):c.2437C>A (p.Pro813Thr)

Genes:
LOC126862575:CDK7 strongly-dependent group 2 enhancer GRCh37_chr17:43344006-43345205 [Gene]
MAP3K14-AS1:MAP3K14 antisense RNA 1 [Gene - HGNC]
MAP3K14:mitogen-activated protein kinase kinase kinase 14 [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
17q21.31
Genomic location:
Preferred name:
NM_003954.5(MAP3K14):c.2437C>A (p.Pro813Thr)
HGVS:
  • NC_000017.11:g.45266678G>T
  • NG_033823.1:g.55371C>A
  • NG_087072.1:g.140G>T
  • NM_003954.5:c.2437C>AMANE SELECT
  • NP_003945.2:p.Pro813Thr
  • LRG_1222t1:c.2437C>A
  • LRG_1222:g.55371C>A
  • LRG_1222p1:p.Pro813Thr
  • NC_000017.10:g.43344045G>T
Protein change:
P813T
Molecular consequence:
  • NM_003954.5:c.2437C>A - missense variant - [Sequence Ontology: SO:0001583]

Condition(s)

Name:
NIK deficiency
Synonyms:
Primary immunodeficiency with multifaceted aberrant lymphoid immunity
Identifiers:
MONDO: MONDO:0018642; MedGen: C5680065; Orphanet: 447731

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV003486030Invitae
criteria provided, single submitter

(Invitae Variant Classification Sherloc (09022015))
Uncertain significance
(Dec 13, 2021)
germlineclinical testing

PubMed (1)
[See all records that cite this PMID]

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

Sherloc: a comprehensive refinement of the ACMG-AMP variant classification criteria.

Nykamp K, Anderson M, Powers M, Garcia J, Herrera B, Ho YY, Kobayashi Y, Patil N, Thusberg J, Westbrook M; Invitae Clinical Genomics Group., Topper S.

Genet Med. 2017 Oct;19(10):1105-1117. doi: 10.1038/gim.2017.37. Epub 2017 May 11. Erratum in: Genet Med. 2020 Jan;22(1):240-242.

PubMed [citation]
PMID:
28492532
PMCID:
PMC5632818

Details of each submission

From Invitae, SCV003486030.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (1)

Description

This sequence change replaces proline, which is neutral and non-polar, with threonine, which is neutral and polar, at codon 813 of the MAP3K14 protein (p.Pro813Thr). The frequency data for this variant in the population databases is considered unreliable, as metrics indicate poor data quality at this position in the gnomAD database. This variant has not been reported in the literature in individuals affected with MAP3K14-related conditions. Experimental studies and prediction algorithms are not available or were not evaluated, and the functional significance of this variant is currently unknown. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Dec 24, 2023